Loading...
Structured benefit–risk evaluation for medicinal products: review of quantitative benefit–risk assessment findings in the literature
A favorable benefit–risk profile remains an essential requirement for marketing authorization of medicinal drugs and devices. Furthermore, prior subjective, implicit and inconsistent ad hoc benefit–risk assessment methods have rightly evolved towards more systematic, explicit or “structured” approac...
Na minha lista:
| Udgivet i: | Ther Adv Drug Saf |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
SAGE Publications
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7727082/ https://ncbi.nlm.nih.gov/pubmed/33343857 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2042098620976951 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|